Search results for "PORIN"

showing 10 items of 260 documents

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (E…

2015

Summary Background Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. Aim To evaluate efficacy and safety of ALV plus peginterferon-α2a and ribavirin (PR) in treatment-naive patients with chronic HCV genotype 1 infection. Methods Double-blind, randomised, placebo-controlled, Phase 3 study evaluating ALV 600 mg once daily [response-guided therapy (RGT) for 24 or 48 weeks or 48 weeks fixed duration] or ALV 400 mg twice daily RGT with PR, compared to PR alone. Following a Food and Drug Administration partial clinical hold, ALV/placebo was discontinued and patients completed treatment with PR only. At that…

MalePhases of clinical researchHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundMedicinePharmacology (medical)ChronicAlisporivirAdolescent; Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young AdultGastroenterologyHepatitis CRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeCombinationCyclosporineDrug Therapy CombinationFemaleHumanUnited StateAdultmedicine.medical_specialtyAdolescentGenotypeAlpha interferonPlaceboAntiviral AgentsYoung AdultDrug TherapyDouble-Blind MethodInternal medicineRibavirinHumansAdverse effectAgedAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseaseUnited StatesRegimenchemistryImmunologybusinessAlimentary pharmacologytherapeutics
researchProduct

First Evidence for a Crosstalk Between Mitochondrial and NADPH Oxidase-Derived Reactive Oxygen Species in Nitroglycerin-Triggered Vascular Dysfunction

2008

Chronic nitroglycerin treatment results in development of nitrate tolerance associated with endothelial dysfunction (ED). We sought to clarify how mitochondria- and NADPH oxidase (Nox)-derived reactive oxygen species (ROS) contribute to nitrate tolerance and nitroglycerin-induced ED. Nitrate tolerance was induced by nitroglycerin infusion in male Wistar rats (100 microg/h/4 day) and in C57/Bl6, p47(phox/) and gp91(phox/) mice (50 microg/h/4 day). Protein and mRNA expression of Nox subunits were unaltered by chronic nitroglycerin treatment. Oxidative stress was determined in vascular rings and mitochondrial fractions of nitroglycerin-treated animals by L-012 enhanced chemiluminescence, revea…

MalePhysiologyVasodilator AgentsClinical BiochemistryMitochondrionPharmacologymedicine.disease_causeBiochemistryMitochondria HeartMiceNitroglycerinchemistry.chemical_compoundEthidiumAortaChromatography High Pressure LiquidHeart metabolismGeneral Environmental Sciencechemistry.chemical_classificationNADPH oxidasebiologyReverse Transcriptase Polymerase Chain ReactionReactive Nitrogen SpeciesBiochemistryCyclosporinecardiovascular systemcirculatory and respiratory physiologyBlotting WesternIn Vitro TechniquesTransfectionCell LineRotenonemedicineAnimalsHumansRNA MessengerRats WistarMolecular BiologyReactive oxygen speciesNADPH OxidasesCell BiologyRotenoneRatsMice Inbred C57BLchemistryMitochondrial permeability transition poreVasoconstrictionApocyninbiology.proteinGeneral Earth and Planetary SciencesReactive Oxygen SpeciesOxidative stressAntioxidants & Redox Signaling
researchProduct

Synaptic vesicle alterations in rod photoreceptors of synaptophysin-deficient mice.

2001

Abstract The abundance of the integral membrane protein synaptophysin in synaptic vesicles and its multiple possible functional contributions to transmitter exocytosis and synaptic vesicle formation stand in sharp contrast to the observed lack of defects in synaptophysin knockout mice. Assuming that deficiencies are compensated by the often coexpressed synaptophysin isoform synaptoporin, we now show that retinal rod photoreceptors, which do not synthesize synaptoporin either in wild-type or in knockout mice, are affected by the loss of synaptophysin. Multiple pale-appearing photoreceptors, as seen by electron microscopy, possess reduced cytoplasmic electron density, swollen mitochondria, an…

MalePresynaptic TerminalsSynaptophysinAction PotentialsFluorescent Antibody TechniqueDark AdaptationBiologyRibbon synapseSynaptic vesicleSynaptic TransmissionExocytosisExocytosisMiceRetinal Rod Photoreceptor CellsElectroretinographySynaptic vesicle recyclingAnimalsMice KnockoutSex CharacteristicsGeneral NeuroscienceVesicleMembrane ProteinsClathrin-Coated VesiclesSynaptoporinCell biologyMice Inbred C57BLMicroscopy ElectronProtein TransportKnockout mouseSynaptophysinbiology.proteinFemaleSynaptic VesiclesNeurosciencePhotic StimulationNeuroscience
researchProduct

Determinants of enhanced thromboxane biosynthesis in renal transplantation

2001

Determinants of enhanced thromboxane biosynthesis in renal transplantation.BackgroundDespite great improvement in patient and graft survival, the long-term morbidity and mortality in renal transplant recipients (RTRs) are still significant, with a high incidence of cardiovascular disease-related deaths.MethodsWe investigated thromboxane (TXA2) biosynthesis and endothelial and coagulative activation in 65 patients who received a renal transplant.ResultsThe rate of TXA2 biosynthesis (urinary 11-dehydro-TXB2 excretion largely reflects platelet TXA2 production in vivo) was significantly (P < 0.0001) higher in RTRs than in healthy subjects. Plasma von Willebrand factor (vWF) and thrombin-antithr…

MaleSettore MED/09 - Medicina InternaThromboxanegraft survivalThromboxanevon Willebrand factorImmunosuppressive AgentThromboxane A2chemistry.chemical_compoundReference ValuesRenal Dialysicardiovascular diseaseReference ValuePlateletPostoperative PeriodKidney transplantationKidneyimmunosuppressionnephrotoxicityThromboxanesMiddle AgedCholesterolmedicine.anatomical_structureNephrologyCyclosporineFemaleCardiovascular disease; Graft survival; Immunosuppression; Kidney transplantation; Nephrotoxicity; Von Willebrand factor; Adult; Antithrombin III; Cardiovascular Diseases; Cholesterol; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Peptide Hydrolases; Postoperative Period; Reference Values; Renal Dialysis; Thromboxanes; von Willebrand Factor; Kidney Transplantation; NephrologyImmunosuppressive AgentsHumancirculatory and respiratory physiologyAdultmedicine.medical_specialtyAntithrombin IIIUrologykidney transplantationFollow-Up StudieEndothelial activationRenal DialysismedicineHumansPlatelet activationcardiovascular disease; cardiovascular diseases; graft survival; immunosuppression; kidney transplantation; nephrotoxicity; von willebrand factorbusiness.industrymedicine.diseasecardiovascular diseasesTransplantationPeptide HydrolasechemistryImmunologybusinessFollow-Up StudiesPeptide HydrolasesKidney International
researchProduct

The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in …

2017

Introduction: Female sex has been shown to be a risk factor for the development of adverse drug reactions; however, this has not been studied for cyclosporine (CsA). The aim of this study was to investigate, in Italian dermatological practice, the influence of gender and menopause and related hormones on the incidence of adverse events (AEs) during CsA treatment in psoriatic patients. Methods: Multicenter, prospective, observational study conducted from May 2011 to June 2013. Patients with plaque psoriasis, undergoing a new CsA administration course, or about to start it, were enrolled in the outpatient clinics of Italian dermatological centers. During the 2–6 months of study duration, pati…

MaleSex FactorRate ratio030226 pharmacology & pharmacyGonadal Steroid HormoneSeverity of Illness Index0302 clinical medicineOutpatient clinicAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; PsoriasisPharmacology (medical)030212 general & internal medicineProspective StudiesProspective cohort studyGonadal Steroid HormonesOriginal ResearchIncidence (epidemiology)IncidenceMedicine (all)General MedicineMiddle AgedMenopausePostmenopauseItalyCyclosporineFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanAdultmedicine.medical_specialtyAdolescentAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis; Adolescent; Adult; Cyclosporine; Female; Gonadal Steroid Hormones; Humans; Incidence; Italy; Male; Middle Aged; Postmenopause; Prospective Studies; Psoriasis; Severity of Illness Index; Sex Factors; Young Adult; Pharmacology (medical)Adverse drug reactionDermatology03 medical and health sciencesYoung AdultSex FactorsInternal medicineSeverity of illnessmedicineHumansPsoriasisRisk factorAdverse effectPsoriasibusiness.industryGendermedicine.diseaseSurgeryAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis; Medicine (all); Pharmacology (medical)Prospective StudiebusinessAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis;
researchProduct

Intestinal transport of cefuroxime axetil in rats: absorption and hydrolysis processes.

2002

Studies were performed using three cefuroxime axetil solutions (11.8, 118 and 200 microM) in three selected intestinal segments and one cefuroxime axetil solution (118 microM) in colon of anaesthetized rats. First-order absorption rate pseudoconstants, k(ap) and effective permeability coefficients, P(eff), were calculated in each set. Absorption of cefuroxime axetil can apparently be described as a carrier-mediated transport, which obeys Michaelis-Menten and first order kinetics in the proximal segment of the small intestine and a passive diffusion mechanism in the mean and distal segments. The absorption kinetic parameters for cefuroxime axetil were obtained: Vm=0.613 (0.440) microM min-1;…

MaleStereochemistryPharmaceutical ScienceModels BiologicalIntestinal absorptionPharmacokineticsmedicineAnimalsProdrugsIntestinal MucosaRats WistarBiotransformationAntibacterial agentCefuroximeIntestinal permeabilityChromatographyChemistryHydrolysisBiological TransportProdrugmedicine.diseaseSmall intestineCephalosporinsRatsPerfusionmedicine.anatomical_structureIntestinal AbsorptionCefadroxilCefuroximeAlgorithmsmedicine.drugInternational journal of pharmaceutics
researchProduct

Role of calcineurin in Ca2+-induced release of catecholamines and neuropeptides

1998

Neurotransmission requires rapid docking, fusion, and recycling of neurotransmitter vesicles. Several of the proteins involved in this complex Ca2+-regulated mechanism have been identified as substrates for protein kinases and phosphatases, e.g., the synapsins, synaptotagmin, rabphilin3A, synaptobrevin, munc18, MARCKS, dynamin I, and B-50/GAP-43. So far most attention has focused on the role of kinases in the release processes, but recent evidence indicates that phosphatases may be as important. Therefore, we investigated the role of the Ca2+/calmodulin-dependent protein phosphatase calcineurin in exocytosis and subsequent vesicle recycling. Calcineurin-neutralizing antibodies, which blocke…

MaleSynaptobrevinCYCLOSPORINE-APhosphataseCalcineurin InhibitorsB-50 GAP-43Biologydynamin IBiochemistryBRAIN NERVE-TERMINALSExocytosisSynaptotagmin 1SincalidephosphataseGeneeskundeCellular and Molecular NeuroscienceNorepinephrineBacterial ProteinsPERMEATED SYNAPTOSOMESAnimalsratNEUROTRANSMITTER RELEASEMARCKSEnzyme InhibitorsRats WistarPROTEIN-KINASE-CDynaminCalcineurinTRANSMITTER RELEASEDYNAMIN-ISynapsinPhosphoric Monoester HydrolasesRatsINDUCED NORADRENALINE RELEASECalcineurinBiochemistryImmunoglobulin GStreptolysinsCalciumexocytosisCALMODULIN-BINDINGSynaptosomes
researchProduct

Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease.

2015

The small heterodimer partner (SHP) (NR0B2) is an atypical nuclear receptor that lacks a DNA-binding domain. It interacts with and inhibits many transcription factors, affecting key metabolic processes, including bile acid, cholesterol, fatty acid, and drug metabolism. Our aim was to determine the influence of steatotic drugs and nonalcoholic fatty liver disease (NAFLD) on SHP expression and investigate the potential mechanisms. SHP was found to be repressed by steatotic drugs (valproate, doxycycline, tetracycline, and cyclosporin A) in cultured hepatic cells and the livers of different animal models of NAFLD: iatrogenic (tetracycline-treated rats), genetic (glycine N-methyltransferase-defi…

MaleTranscription GeneticThiazepinesResponse elementReceptors Cytoplasmic and NuclearBiologyMiceNon-alcoholic Fatty Liver DiseaseCyclosporin amedicineCCAAT-Enhancer-Binding Protein-alphaAnimalsHumansProtein kinase APromoter Regions GeneticTranscription factorCells CulturedPharmacologyMitogen-Activated Protein Kinase 1KinaseValproic AcidFatty liverTetracyclinemedicine.diseaseFatty LiverDoxycyclineCancer researchSmall heterodimer partnerCyclosporineMolecular MedicineSignal transductionSignal TransductionMolecular pharmacology
researchProduct

Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.

2010

Summary Background Duchenne muscular dystrophy is a rare X-linked progressive disease characterised by loss of ambulation at about age 10 years, with death in early adulthood due to respiratory and cardiac insufficiency. Steroids are effective at slowing the progression of muscle weakness; however, their use is limited by side-effects, prompting the search for alternatives. We assessed the effect of ciclosporin A as monotherapy and in combination with intermittent prednisone for the treatment of ambulant patients with this disorder. Methods Our study was a parallel-group, placebo-controlled, double-blind, multicentre trial at trial sites of the German muscular dystrophy network, MD-NET, ove…

Malemedicine.medical_specialtyDuchenne muscular dystrophyMedizinPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawPrednisoneInternal medicinemedicineHumansMuscular dystrophyChild030304 developmental biology0303 health sciencesbusiness.industryMuscle weaknessmedicine.diseaseCiclosporin3. Good healthSurgeryClinical trialMuscular Dystrophy DuchenneReview Literature as TopicTreatment OutcomeCyclosporineNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerymedicine.drugThe Lancet. Neurology
researchProduct

Reversal of Endothelial Nitric Oxide Synthase Uncoupling and Up-Regulation of Endothelial Nitric Oxide Synthase Expression Lowers Blood Pressure in H…

2006

Objectives We sought to examine the hypothesis that a pharmacologic up-regulation of endothelial nitric oxide synthase (eNOS) combined with a reversal of eNOS uncoupling provides a protective effect against cardiovascular disease. Background Many cardiovascular diseases are associated with oxidant stress involving protein kinase C (PKC) and uncoupling of eNOS. Methods Messenger ribonucleic acid (mRNA) expression was analyzed with RNase protection assay or quantitative real-time polymerase chain reaction, vascular nitric oxide (NO) with spin trapping, and reactive oxygen species (ROS) with dihydroethidium fluorescence. Results Aortas of spontaneously hypertensive rats (SHR) showed an elevate…

Malemedicine.medical_specialtyEndotheliumRats Inbred WKYNitric oxidechemistry.chemical_compoundEnosInternal medicineRats Inbred SHRMedicineAnimalsMidostaurinEnzyme InhibitorsProtein Kinase Cbiologybusiness.industryNOX4biology.organism_classificationStaurosporineRatsUp-RegulationNitric oxide synthaseEndocrinologymedicine.anatomical_structurechemistryHypertensionbiology.proteincardiovascular systemP22phoxEndothelium VascularNitric Oxide SynthasebusinessCardiology and Cardiovascular MedicineNicotinamide adenine dinucleotide phosphateJournal of the American College of Cardiology
researchProduct